The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells

Biochemical Pharmacology

Volumn 74, Issue 11, 2007, Pages 1587-1595

  Herst, P M ^a   Petersen, T ^a   Jerram, P ^a   Baty, J ^a   Berridge, M V ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

Author keywords

Anticancer drug; Apoptosis; Mechanism of action; Phenoxodiol; Plasma membrane electron transport; T cells

Indexed keywords

CARBOPLATIN; CASPASE; DOXORUBICIN; FLICE INHIBITORY PROTEIN; GEMCITABINE; ISOFLAVONE; PACLITAXEL; PHENOXODIOL; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER; CANCER CELL CULTURE; CELL MEMBRANE TRANSPORT; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ELECTRON TRANSPORT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; LYMPHOCYTE PROLIFERATION; MITOCHONDRIAL GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOXORUBICIN; ELECTRON TRANSPORT; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; ISOFLAVONES; MALE; MICE; MICE, INBRED C57BL; MULTIENZYME COMPLEXES; NADH, NADPH OXIDOREDUCTASES; SPLEEN; T-LYMPHOCYTES;

EID: 35348931655     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.08.019     Document Type: Article

References (21)

1. Constantinou A.I., and Husband A. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res 22 5 (2002) 2581-2585
2. Choueiri T.K., Mekhail T., Hutson T.E., Ganapathi R., Kelly G.E., and Bukowski R.M. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol 17 5 (2006) 860-865
3. Alvero A.B., O'Malley D., Brown D., Kelly G., Garg M., Chen W., et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 106 3 (2006) 599-608
4. Kamsteeg M., Rutherford T., Sapi E., Hanczaruk B., Shahabi S., Flick M., et al. Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 22 17 (2003) 2611-2620
5. Kluger H.M., McCarthy M.M., Alvero A.B., Sznol M., Ariyan S., Camp R.L., et al. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by phenoxodiol is associated with carboplatin sensitization. J Trans Med 5 (2007) 1-15
6. Aguero M.F., Facchinetti M.M., Sheleg Z., and Senderowicz A.M. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res 65 8 (2005) 3364-3373
7. 2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. Biofactors 25 1-4 (2005) 43-60
8. Pelicano H., Xu R.H., Du M., Feng L., Sasaki R., Carew J.S., et al. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 175 6 (2006) 913-923
9. Herst P.M., and Berridge M.V. Plasma membrane electron transport: a new target for cancer drug development. Curr Mol Med 6 (2006) 895-904
10. Ly J.D., and Lawen A. Transplasma membrane electron transport: enzymes involved and biological function. Redox Rep 8 1 (2003) 3-21
11. Berridge M.V., and Tan A.S. High-capacity redox control at the plasma membrane of mammalian cells: trans-membrane, cell surface, and serum NADH-oxidases. Antiox Redox Signal 2 (2000) 231-242
12. Herst P.M., Tan A.S., Scarlett D.J., and Berridge M.V. Cell surface oxygen consumption by mitochondrial gene knockout cells. Biochim Biophys Acta 1656 2-3 (2004) 79-87
13. Morré D.J., Chueh P.-J., Yazig K., Balicki A., Kim C., and Morré D.M. ECTO-NOX target for the anticancer isoflavene phenoxodiol. Oncology Research 16 (2007) 299-312
14. Chueh P.J., Kim C., Cho N., Morré D.M., and Morré D.J. Molecular cloning and characterization of a tumor-associated, growth-related, and time-keeping hydroquinone (NADH) oxidase (tNOX) of the HeLa cell surface. Biochemistry 41 11 (2002) 3732-3741
15. Morré D.J., Sedlak D., Tang X., Chueh P.J., Geng T., and Morré D.M. Surface NADH oxidase of HeLa cells lacks intrinsic membrane binding motifs. Arch Biochem Biophys 392 2 (2001) 251-256
16. Scarlett D-JG, Herst P.M., Tan A.S., Prata C., and Berridge M.V. Mitochondrial gene-knockout (ro) cells: a versatile model for exploring the secrets of trans-plasma membrane electron transport. Biofactors 20 (2004) 213-220
17. King M.P., and Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246 4929 (1989) 500-503
18. Berridge M.V., and Tan A.S. Cell-surface NAD(P)H-oxidase: relationship to trans-plasma membrane NADH-oxidoreductase and a potential source of circulating NADH-oxidase. Antiox Redox Signal 2 (2000) 277-288
19. Berridge M.V., and Tan A.S. Trans-plasma membrane electron transport: a cellular assay for NADH- and NADPH-oxidase based on extracellular, superoxide-mediated reduction of the sulfonated tetrazolium salt WST-1. Protoplasma 205 1-4 (1998) 74-82
20. Scarlett D.J., Herst P.M., and Berridge M.V. Multiple proteins with single activities or a single protein with multiple activities: the conundrum of cell surface NADH oxidoreductases. Biochim Biophys Acta 1708 1 (2005) 108-119
21. Gamble J.R., Xia P., Hahn C.N., Drew J.J., Drogemuller C.J., Brown D., et al. An experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer 118 10 (2006) 2412-2420